Cardiovascular

FDA approves Kcentra for urgent reversal of anticoagulation in adults

On April 29, the U.S. Food and Drug Administration (FDA) approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding. Plasma is the only other product approved for this use in the United States; Kcentra doesn’t require blood group typing or thawing, so it can be administered more quickly than frozen plasma. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares